Clinical Trials Using Sipuleucel-T
Clinical trials are research studies that involve people. The clinical trials on this list are studying Sipuleucel-T. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Immediate or Delayed Ipilimumab after Sipuleucel-T Treatment in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies the effects of taking ipilimumab as an immediate or delayed treatment after sipuleucel-T treatment on castration-resistant prostate cancer that has spread to other places in the body. Sipuleucel-T uses the immune system to fight the disease and attack prostate cancer cells. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ipilimumab blocks different components of the immune system in order to enhance the immune system’s ability to fight diseases. It is not yet known whether giving ipilimumab as an immediate treatment or as a delayed treatment is more effective in treating prostate cancer.
Location: 2 locations
Sipuleucel-T with or without Low-Protein Diet in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
This randomized pilot phase II trial studies how well sipuleucel-T with or without low-protein diet works in treating patients with castration-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Giving a low-protein diet may help sipuleucel-T work better than it does when giving with a standard protein-diet in treating patients with prostate cancer.
Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Atezolizumab and Sipuleucel-T in Treating Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
This randomized phase Ib trial study will assess the sequence of the administration of atezolizumab and sipuleucel-T and to see how well they work in treating patients with castration resistant metastatic prostate cancer without symptoms or with minimal symptoms. Atezolizumab may enhance the body's ability to recognize abnormal, tumor cells. Vaccines, such as sipuleucel-T, made from a person’s white blood cells mixed with tumor proteins may help the body build an effective immune response to kill prostate tumor cells. Giving atezolizumab and sipuleucel-T may work better in treating patients with castration resistant metastatic prostate cancer.
Location: University of Hawaii at Manoa, Honolulu, Hawaii
Sipuleucel-T and Stereotactic Ablative Body Radiation Therapy in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies how well sipuleucel-T and stereotactic body radiation therapy (stereotactic ablative body radiation therapy) work in treating patients with prostate cancer that does not respond to hormone therapy that has spread to other places in the body (metastatic). Vaccines made from a person’s white blood cells mixed with tumor proteins may help the body build an effective immune response to kill prostate cancer cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving sipuleucel-T with stereotactic ablative body radiation therapy may kill more tumor cells.
Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to subjects followed on active surveillance as standard of care.
Location: 7 locations